Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
USANA Health Sciences, Inc is a household & personal products business based in the US. USANA Health Sciences shares (USNA) are listed on the NYSE and all prices are listed in US Dollars.
|52-week range||USD$43.01 - USD$100.71|
|50-day moving average||USD$88.1418|
|200-day moving average||USD$80.2114|
|Wall St. target price||USD$113.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$5.86|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing USANA Health Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of USANA Health Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
USANA Health Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, USANA Health Sciences shares trade at around 17x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
USANA Health Sciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.0608. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into USANA Health Sciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
USANA Health Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$190.5 million.
The EBITDA is a measure of a USANA Health Sciences's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$1.1 billion|
|Operating margin TTM||15.56%|
|Gross profit TTM||USD$925.5 million|
|Return on assets TTM||19.05%|
|Return on equity TTM||31.43%|
|Market capitalisation||USD$2.1 billion|
TTM: trailing 12 months
There are currently 682,849 USANA Health Sciences shares held short by investors – that's known as USANA Health Sciences's "short interest". This figure is 11.6% down from 772,470 last month.
There are a few different ways that this level of interest in shorting USANA Health Sciences shares can be evaluated.
USANA Health Sciences's "short interest ratio" (SIR) is the quantity of USANA Health Sciences shares currently shorted divided by the average quantity of USANA Health Sciences shares traded daily (recently around 106862.12832551). USANA Health Sciences's SIR currently stands at 6.39. In other words for every 100,000 USANA Health Sciences shares traded daily on the market, roughly 6390 shares are currently held short.
However USANA Health Sciences's short interest can also be evaluated against the total number of USANA Health Sciences shares, or, against the total number of tradable USANA Health Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case USANA Health Sciences's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 USANA Health Sciences shares in existence, roughly 30 shares are currently held short) or 0.0606% of the tradable shares (for every 100,000 tradable USANA Health Sciences shares, roughly 61 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against USANA Health Sciences.
Find out more about how you can short USANA Health Sciences stock.
We're not expecting USANA Health Sciences to pay a dividend over the next 12 months.
USANA Health Sciences's shares were split on a 2:1 basis on 23 November 2016. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your USANA Health Sciences shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for USANA Health Sciences shares which in turn could have impacted USANA Health Sciences's share price.
Over the last 12 months, USANA Health Sciences's shares have ranged in value from as little as $43.01 up to $100.71. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while USANA Health Sciences's is 0.9792. This would suggest that USANA Health Sciences's shares are less volatile than average (for this exchange).
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products, which provide macro-nutrition. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.